“We are executing well in our ongoing registrational studies of daraxonrasib in patients with previously treated PDAC and NSCLC, and continuing preparations to start the earlier-line PDAC trials this year. Today we’ve shared important data from all three of our clinical-stage investigational RAS(ON) inhibitors that reinforce exciting opportunities in NSCLC,” said Mark A. Goldsmith, chief executive officer and chairman of Revolution Medicines (RVMD). “As we continue growing our commercial and operational capabilities and advancing launch readiness activities, I’m pleased to welcome Anthony Mancini to our executive team.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Positive Clinical Data and Competitive Efficacy Drive Buy Rating for Revolution Medicines’ Zoldonrasib
- Revolution Medicines shares up 6% after presenting initial RMC-9805 study data
- Promising Phase 1 Results for Revolution Medicines’ Zoldonrasib in NSCLC Support Buy Rating
- Revolution Medicines: Promising Phase 3 Progress and Strong RAS-ON Platform Drive Buy Rating
- Revolution Medicines price target lowered to $64 from $78 at Stifel